1.18
0.02 (1.72%)
| Previous Close | 1.16 |
| Open | 1.18 |
| Volume | 101,704 |
| Avg. Volume (3M) | 176,220 |
| Market Cap | 70,935,816 |
| Price / Sales | 30.83 |
| Price / Book | 117.27 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Operating Margin (TTM) | -6,217.44% |
| Diluted EPS (TTM) | -3.27 |
| Quarterly Revenue Growth (YOY) | 0.40% |
| Total Debt/Equity (MRQ) | 6,298.14% |
| Current Ratio (MRQ) | 5.71 |
| Operating Cash Flow (TTM) | -143.10 M |
| Levered Free Cash Flow (TTM) | -75.65 M |
| Return on Assets (TTM) | -36.78% |
| Return on Equity (TTM) | -245.59% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | IGM Biosciences, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.10 |
|
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 37.57% |
| % Held by Institutions | 47.53% |
| 52 Weeks Range | ||
| Median | 1.00 (-15.25%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 11 Jun 2025 | 1.00 (-15.25%) | Hold | 1.27 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 1.12 | - | 1,906 | 2,135 |
| BEHRENS M KATHLEEN | 1.12 | - | 1,471 | 1,648 |
| LEE MICHAEL STEWART | 1.12 | - | 828 | 927 |
| REDMILE GROUP, LLC | 1.12 | - | 828 | 927 |
| THOMPSON ELIZABETH H.Z. | 1.12 | - | 694 | 777 |
| TOPSOE CHRISTINA TENG | 1.12 | - | 1,284 | 1,438 |
| TOPSOE JAKOB HALDOR | 1.12 | - | 828 | 927 |
| Aggregate Net Quantity | 7,839 | |||
| Aggregate Net Value ($) | 8,780 | |||
| Aggregate Avg. Buy ($) | 1.12 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| REDMILE GROUP, LLC | Director | 30 Jun 2025 | Acquired (+) | 828 | 1.12 | 927 |
| LEE MICHAEL STEWART | Director | 30 Jun 2025 | Acquired (+) | 828 | 1.12 | 927 |
| BAKER BROS. ADVISORS LP | Director | 30 Jun 2025 | Acquired (+) | 1,906 | 1.12 | 2,135 |
| BEHRENS M KATHLEEN | Director | 30 Jun 2025 | Acquired (+) | 1,471 | 1.12 | 1,648 |
| THOMPSON ELIZABETH H.Z. | Director | 30 Jun 2025 | Acquired (+) | 694 | 1.12 | 777 |
| TOPSOE CHRISTINA TENG | Director | 30 Jun 2025 | Acquired (+) | 1,284 | 1.12 | 1,438 |
| TOPSOE JAKOB HALDOR | Director | 30 Jun 2025 | Acquired (+) | 828 | 1.12 | 927 |
| Date | Type | Details |
|---|---|---|
| 01 Jul 2025 | Announcement | IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |